Latest news with #Zemansky
Business Insider
10-08-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Globus Medical (GMED) and BioMarin Pharmaceutical (BMRN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kura Oncology (KURA – Research Report), Globus Medical (GMED – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kura Oncology (KURA) Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Kura Oncology on August 8 and set a price target of $27.00. The company's shares closed last Friday at $5.54. According to Zemansky is a 4-star analyst with an average return of 7.4% and a 52.1% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Acumen Pharmaceuticals, and Syndax Pharmaceuticals. Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $25.78, a 352.3% upside from current levels. In a report issued on August 7, LifeSci Capital also maintained a Buy rating on the stock with a $24.00 price target. Globus Medical (GMED) In a report issued on August 8, Craig Bijou from Bank of America Securities reiterated a Hold rating on Globus Medical, with a price target of $65.00. The company's shares closed last Friday at $58.65. According to Bijou is a 3-star analyst with an average return of 1.0% and a 43.9% success rate. Bijou covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Bausch + Lomb Corporation, and Merit Medical Systems. Currently, the analyst consensus on Globus Medical is a Moderate Buy with an average price target of $82.90, implying a 48.0% upside from current levels. In a report issued on August 8, Needham also maintained a Hold rating on the stock. BioMarin Pharmaceutical (BMRN) Bank of America Securities analyst Jason Gerberry maintained a Buy rating on BioMarin Pharmaceutical on August 8 and set a price target of $103.00. The company's shares closed last Friday at $57.33. According to Gerberry is a 3-star analyst with an average return of 2.3% and a 49.5% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Amphastar Pharmaceuticals, and Tarsus Pharmaceuticals. Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $97.95, which is a 65.1% upside from current levels. In a report issued on July 28, Piper Sandler also maintained a Buy rating on the stock with a $122.00 price target.
Yahoo
10-06-2025
- Business
- Yahoo
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, lowering the price forecast from $32 to $18. Zemansky noted that Keros has wrapped up its strategic review, with the board deciding to advance KER-065 for Duchenne muscular dystrophy (DMD) and return $375 million in excess capital to shareholders. The analyst highlights that the stock has been downgraded not due to concerns about the platform or pipeline, which remains compelling, but because of limited near-term favorable valuation and a solid cash buffer, Zemansky writes that the stock may stay range-bound given that meaningful updates on KER-065 are unlikely soon, with FDA discussions not expected until the third quarter. As a result, other investment opportunities may offer better near-term potential. The analyst slashed the price forecast to reflect adjustments to the cash balance and a higher weighted average cost of capital (WACC) of 16%, now aligned with peers at a similar stage. On June 9, 2025, ADAR1 Capital Management, the largest shareholder of Keros Therapeutics, stated that the recent board election results signal 'widespread dissatisfaction' among investors. ADAR1 highlighted that two directors received support from only about a third of outstanding shares, reflecting a loss of confidence in the board's management and capital allocation. While acknowledging Keros's recent decision to halt a drug program and cut staff, ADAR1 called the actions 'wholly insufficient.' The firm heavily criticized the board's plan to return only a portion of its cash to shareholders, arguing the amount retained is excessive for Keros's limited clinical pipeline. To address this, ADAR1 issued specific demands for the board to take immediate action. The firm called for Keros to increase its capital return by an additional $100 million for a total of $475 million, to be paid through a special dividend by the end of Q3 2025. Furthermore, ADAR1 urged the company to create a contingent value right (CVR) to allow shareholders to directly benefit from the Takeda partnership. ADAR1 warned that if the board does not adopt a more aggressive, investor-focused strategy, it will not hesitate to nominate new directors for the 2026 annual meeting to ensure the will of shareholders is respected. Zemansky acknowledged that the board had limited strategic options aside from fully dissolving the company. However, he writes that bearish investors may have expected a more aggressive outcome than just the potential $375 million capital return, especially since the exact structure and terms of the buyback remain undecided. Zemansky pointed out that beyond the longer development timelines, overall sentiment toward Keros likely remains cautious, which could continue to pressure the stock. While the company's three board nominees were elected despite activist opposition, a notable portion of votes were withheld for the two targeted candidates, indicating lingering investor discontent. He stresses the point that frustration may persist, particularly given the recent setback with TROPOS and skepticism that last month's cost-cutting measures were sufficient. Although some bulls might argue that the stock has been unfairly punished, especially given the added hurdles of developing drugs that target the TGF-β pathway, Zemansky writes most investors will likely wait for more meaningful progress and risk reduction before 'returning to the story.' Price Action: KROS shares are trading lower by 2.34% to $13.76 at last check Tuesday. Read Next:Image via Shutterstock Date Firm Action From To Dec 2020 SVB Leerink Maintains Outperform Dec 2020 HC Wainwright & Co. Maintains Buy May 2020 Piper Sandler Maintains Overweight View More Analyst Ratings for KROS View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
